VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells

Authors
Moody, TW Leyton, J Chan, D Brenneman, DC Fridkin, M Gelber, E Levy, A Gozes, I
Citation
Tw. Moody et al., VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells, BREAST CANC, 68(1), 2001, pp. 55-64
Citations number
40
Categorie Soggetti
Oncology,"Onconogenesis & Cancer Research
Journal title
BREAST CANCER RESEARCH AND TREATMENT
ISSN journal
01676806 → ACNP
Volume
68
Issue
1
Year of publication
2001
Pages
55 - 64
Database
ISI
SICI code
0167-6806(200107)68:1<55:VRAACD>2.0.ZU;2-F
Abstract
The effects of vasoactive intestinal peptide (VIP) antagonists on breast ca ncer cells were investigated. (N-stearyl, norleucine(17))VIP hybrid ((SN)VI Phyb) inhibited specific (1)25I-VIP binding to MCF7, SKBR3, T47D ZR75-1 and MDA-MB231 cells with high affinity (IC(5)0 values of 0.03-0.06 muM). (SN)V IPhyb,1 muM, inhibited the ability of 10 nM VIP to cause elevation of cAMP and to increase c-fos mRNA. Micromolar concentrations of (SN)VIPhyb inhibit ed the proliferation of MDA-MB231 or MCF7 cells using a MTT and clonogenic assay. Using a MTT assay, (SN)VIPhyb enhanced the ability of taxol and doxo rubicin to inhibit breast cancer growth. Using nude mice bearing MDA-MB231 xenografts, VIPhyb potentiated the ability of taxol to inhibit proliferatio n. The results indicate that VIP receptor antagonists increase the ability of chemotherapeutic drugs to kill breast cancer cells.